Interventions to combat or prevent drug counterfeiting: A systematic review

dc.contributor.authorEl-Jardali, Fadi
dc.contributor.authorAkl, Elie A.
dc.contributor.authorFadlallah, Racha
dc.contributor.authorOliver, Sandy R.
dc.contributor.authorSaleh, Nadine G.
dc.contributor.authorEl-Bawab, Lamya
dc.contributor.authorRizk, Rana G.
dc.contributor.authorFarha, A. A.
dc.contributor.authorHamra, Rasha
dc.contributor.departmentCenter for Systematic Reviews on Health Policy and Systems Research (SPARK)
dc.contributor.departmentHealth Management and Policy (HMPD)
dc.contributor.departmentInternal Medicine
dc.contributor.departmentEpidemiology and Population Health (EPHD)
dc.contributor.departmentLibrary Publications
dc.contributor.facultyCenter for Systematic Reviews on Health Policy and Systems Research (SPARK)
dc.contributor.facultyFaculty of Health Sciences (FHS)
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.facultyUniversity Libraries
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T14:01:49Z
dc.date.available2025-01-24T14:01:49Z
dc.date.issued2015
dc.description.abstractObjective: Drug counterfeiting has serious public health and safety implications. The objective of this study was to systematically review the evidence on the effectiveness of interventions to combat or prevent drug counterfeiting. Data sources: We searched multiple electronic databases and the grey literature up to March 2014. Two reviewers completed, in duplicate and independently, the study selection, data abstraction and risk of bias assessment. Study eligibility criteria, participants and interventions: We included randomised trials, non-randomised studies, and case studies examining any intervention at the health system-level to combat or prevent drug counterfeiting. Outcomes of interest included changes in failure rates of tested drugs and changes in prevalence of counterfeit medicines. We excluded studies that focused exclusively on substandard, degraded or expired drugs, or that focused on medication errors. Appraisal and synthesis: We assessed the risk of bias in each included study. We reported the results narratively and, where applicable, we conducted meta-analyses. Results: We included 21 studies representing 25 units of analysis. Overall, we found low quality evidence suggesting positive effects of drug registration (OR=0.23; 95% CI 0.08 to 0.67), and WHO-prequalification of drugs (OR=0.06; 95% CI 0.01 to 0.35) in reducing the prevalence of counterfeit and substandard drugs. Low quality evidence suggests that licensing of drug outlets is probably ineffective (OR=0.66; 95% CI 0.41 to 1.05). For multifaceted interventions (including a mix of regulations, training of inspectors, public-private collaborations and legal actions), low quality evidence suggest they may be effective. The single RCT provided moderate quality evidence of no effect of 'two extra inspections' in improving drug quality. Conclusions: Policymakers and stakeholders would benefit from registration and WHO-prequalification of drugs and may also consider multifaceted interventions. Future effectiveness studies should address the methodological limitations of the available evidence. © 2015, BMJ. All rights reserved.
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2014-006290
dc.identifier.eid2-s2.0-84926443338
dc.identifier.pmid25787989
dc.identifier.urihttp://hdl.handle.net/10938/34697
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.relation.ispartofBMJ Open
dc.sourceScopus
dc.subjectCounterfeit drugs
dc.subjectFraud
dc.subjectHealth policy
dc.subjectHumans
dc.subjectInternational cooperation
dc.subjectPharmaceutical services, online
dc.subjectPublic health
dc.subjectCounterfeit drug
dc.subjectClinical trial (topic)
dc.subjectConceptual framework
dc.subjectConsumer
dc.subjectDrug counterfeiting
dc.subjectDrug marketing
dc.subjectDrug packaging
dc.subjectHealth care
dc.subjectHospital department
dc.subjectHuman
dc.subjectMedication error
dc.subjectMeta analysis
dc.subjectOutcomes research
dc.subjectPrevalence
dc.subjectPublic-private partnership
dc.subjectRandomized controlled trial (topic)
dc.subjectRegistration
dc.subjectReview
dc.subjectRisk assessment
dc.subjectSystematic review
dc.subjectUnlicensed drug use
dc.subjectHealth care policy
dc.subjectLegislation and jurisprudence
dc.subjectPharmacy
dc.subjectPrevention and control
dc.subjectStatistics and numerical data
dc.titleInterventions to combat or prevent drug counterfeiting: A systematic review
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2015-10301.pdf
Size:
1.06 MB
Format:
Adobe Portable Document Format